GSK3A and diffuse large B-cell lymphoma: Interestingly, single tafasitamab treatment also significantly reduced levels of phospho-GSK3α in all DLBCL cells (Fig. 3A), phospho-mTOR and phospho-p70S6K in SU-DHL10 cells (Fig. 3C), phospho-RPS6 in Toledo and OCI-LY3 cells (Fig. 3E).